Results from a clinical trial led by researchers from the University of Queen Mary in London, Posted today in JamaThey show that providing people with high blood pressure An injection every six months can lead to a significant, prolonged reduction in their blood pressure.
The worldwide test, Kardia-2, included 663 people with high blood pressure, the condition of which was not well-managed with their standard treatment.
In the test, patients were injected by a new Zilebesiran drug, along with standardized blood pressure treatments. Researchers found that the supply to patients Zilebesiran alongside their standard medicine was better to lower blood pressure levels by the standard drug only.
The results could have a major positive impact on those with high blood pressure, which affects about 1 in 3 adults in the United Kingdom and, if left untreated, increases the risk of cardiovascular events such as heart attacks, strokes and even death.
Dr. Manish Saxena, a clinical co-director of the William Harvey Clinical Research Center at Queen Mary University in London and specialist at Barts Health NHS Trust was the lead researcher in the United Kingdom and a senior author in the new publication. Speaking of the results, he said:
“Hypertension is a worldwide concern for health, as blood pressure control rates remain poor and is the leading cause of heart attacks and strokes. This study demonstrates the effectiveness and safety of Zilebesiran when added to drugs that usually reduce front -line blood pressure. The innovation of this treatment is its long duration. Providing only one injection every six months could help millions of patients better manage their condition. ”
Zilebesiran is a research therapeutic that uses RNA interference technology. It excludes the production of a particular protein in the liver (angiotogen), helping blood vessels to relax and reduce blood pressure. The injection is given under the skin.
Next steps for Zilebesiran include another phase 2, Kardia-3 study, to determine whether this treatment is able to be used to treat people with high blood pressure and established cardiovascular disease or those who are at high risk of cardiovascular disease.
Later this year, the sponsor plans to be enrolled in patients in a large worldwide study study to understand its effect on the reduction of cardiovascular events, strokes and cardiovascular death.
The study was funded by Alnylam Pharmaceuticals, with Barts Health NHS Trust serving as head of the test and leading European study in the study.
Source:
Magazine report:
Desai, as, et al. (2025). Additional treatment with zilebesiran for insufficiently controlled hypertension: the randomized Kardia-2 clinical trial. Price. Doi.org/10.1001/jama.2025.6681.
